RB patients with germline RB1 mutation who received EBRT have a high risk of 50% to develop SPMs with advanced age including leiomyosarcoma, OS, melanoma, lung, and bladder cancer [426]. The gene discussed is RB1; the disease is leiomyosarcoma.